Targeting transforming growth factor-β2 by antisense oligodeoxynucleotide accelerates T cell-mediated tumor rejection in a humanized mouse model of triple-negative breast cancer

Cancer Immunol Immunother. 2022 Sep;71(9):2213-2226. doi: 10.1007/s00262-022-03157-w. Epub 2022 Jan 31.

Abstract

Transforming growth factor-beta (TGF-β) pathway mediates suppression of antitumor immunity and is associated with poor prognosis in triple-negative breast cancer (TNBC). In this study, we generated a humanized animal model by transplanting human peripheral blood mononuclear cells into immunodeficient mice followed by inoculation of MDA-MB-231 cells and subsequently analyzed the role of TGF-β2 in the interaction between human T cells and human tumor cells. Following reconstitution of the human immune system, inhibition of TGF-β signaling by TGF-β2 antisense oligodeoxynucleotide (TASO) resulted in accelerated tumor growth inhibition. TGF-β2 inhibition also resulted in downregulation of peripheral Foxp3 + regulatory T cells (Treg), whereas no effect was seen in the expression of CD8 + cytotoxic T cells. Analysis of the TASO-treated mice serum revealed elevated levels of human IFN-γ and reduced levels of human IL-10 and TGF-β2. Moreover, TGF-β2 inhibition resulted in increased CD8 + T cell infiltration, whereas the reduced infiltration of Tregs into the tumor partly resulted from decreased expression of CCL22. Decreased intratumoral Tregs facilitated the activation of cytotoxic T cells, associated with increased granzyme B expression. These results indicate that TASO potentiated T cell-mediated antitumor immunity, and it is proposed that TGF-β2 may be a promising target in the immunotherapeutic strategy of TNBC.

Keywords: Antitumor immunity; Breast cancer; Humanized model; TGF-β2 antisense.

MeSH terms

  • Animals
  • Disease Models, Animal
  • Humans
  • Leukocytes, Mononuclear / metabolism
  • Mice
  • Oligodeoxyribonucleotides, Antisense* / pharmacology
  • T-Lymphocytes, Regulatory
  • Transforming Growth Factor beta2* / antagonists & inhibitors
  • Triple Negative Breast Neoplasms* / pathology

Substances

  • Oligodeoxyribonucleotides, Antisense
  • Transforming Growth Factor beta2